{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:44Z","timestamp":1761183044848,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jiac.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T17:48:50Z","timestamp":1562780930000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8326-4930","authenticated-orcid":false,"given":"Lucio","family":"Boglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Lupia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.06.004_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jiac.2019.06.004_bib2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","article-title":"Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations","volume":"5","author":"Zampino","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jiac.2019.06.004_bib3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jiac.2019.06.004_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4254\/wjh.v8.i12.545","article-title":"Hepatitis C virus and neurological damage","volume":"8","author":"Mathew","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jiac.2019.06.004_bib5","first-page":"208","article-title":"Central nervous system involvement in patients with HCV-related cryoglobulinemia","volume":"315","author":"Origgi","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jiac.2019.06.004_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.psy.41.5.377","article-title":"Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C","volume":"41","author":"Kraus","year":"2000","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jiac.2019.06.004_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2002.30688","article-title":"Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease","volume":"35","author":"Forton","year":"2002","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jiac.2019.06.004_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jiac.2019.06.004_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v66n0106","article-title":"Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction","volume":"66","author":"Raison","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jiac.2019.06.004_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2010.01393.x","article-title":"Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update","volume":"18","author":"Sockalingam","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jiac.2019.06.004_bib11","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-016-0407-2","article-title":"Drug-drug interactions between direct-acting antivirals and psychoactive medications","volume":"55","author":"Smolders","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2019.06.004_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00705-017-3684-7","article-title":"Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens","volume":"163","author":"Boglione","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.jiac.2019.06.004_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12711","article-title":"Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study","volume":"24","author":"Boglione","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jiac.2019.06.004_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.12925","article-title":"Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation","volume":"40","author":"Mullish","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jiac.2019.06.004_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.genhosppsych.2011.10.007","article-title":"Which psychotropic medications induce hepatotoxicity?","volume":"34","author":"Sedky","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jiac.2019.06.004_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003495-200666020-00003","article-title":"Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management","volume":"66","author":"Loftis","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2019.06.004_bib17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2893.2007.00885.x","article-title":"Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans","volume":"14","author":"Butt","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jiac.2019.06.004_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","article-title":"Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study","volume":"18","author":"Sundberg","year":"2018","journal-title":"BMC Psychiatry"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19301734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19301734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:59:10Z","timestamp":1761159550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19301734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1341321X19301734"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.06.004","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}